Chinese biotech HuidaGene reports early success with first CRISPR brain treatment in 9-year-old with MECP2 duplication ...

Alvogen plans to fight a court decision that could significantly delay its ability to bring a generic version of Bausch ...

Gilead's antibody-drug conjugate Trodelvy combined with Merck's Keytruda reduced the risk of disease progression or death in ...

Roivant is changing its strategy for Immunovant roughly a month after its subsidiary decided it wouldn’t take one of its ...

The FDA made two de­ci­sions on Re­gen­eron’s best-sell­ing drugs Fri­day, hand­ing down one ap­proval and one re­jec­tion.

Verve Therapeutics is trying to swerve the gene editing industry downturn with new results on a potential one-time treatment ...

Sanofi is teaming up with a private biotech in Delaware on a pair of bispecific antibodies for autoimmune and inflammatory ...

A hot antibody discovery team in China has signed its second US biotech deal in less than six months, marking the latest sign ...

US brand-name drugs use foreign ingredients, with Europe supplying 43% of APIs, as Trump administration considers 25% tariffs ...

The 340B drug discount program may move under the purview of CMS, according to a leaked HHS restructuring document reviewed ...

Trump's drug pricing EO includes wins on pill penalty reform, faster approvals, and PBM rules, but adds scrutiny on pricing ...

The UK on Thursday authorized GSK’s Blenrep to treat certain multiple myeloma patients in two different regimens, marking the ...